Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Melanoma 23Multiple Myeloma 9Colorectal Neoplasms 9Carcinoma, Non-Small-Cell Lung 9Thyroid Neoplasms 8Glioma 8Neoplasm Metastasis 7Hematologic Neoplasms 6Thyroid Carcinoma, Anaplastic 5Pancreatic Neoplasms 5Lymphoma 5Thyroid Cancer, Papillary 4Neurofibromatosis 1 4Neoplasms 4Lung Neoplasms 3Brain Neoplasms 3Astrocytoma 3Adenocarcinoma, Follicular 3Skin Neoplasms 2Recurrence 2Rectal Neoplasms 2Prostatic Neoplasms 2Ovarian Neoplasms 2Neurofibroma, Plexiform 2Leukemia, Myelomonocytic, Juvenile 2Histiocytosis, Langerhans-Cell 2Glioblastoma 2Colonic Neoplasms 2Advanced Solid Tumors 2Uveal Melanoma 1

Interventions

trametinib 1ribociclib 1nazartinib 1naporafenib 1capmatinib 1Gefitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
EGFR-mutant Non-small Cell Lung Cancer × trametinib × 1 year × Clear all
NCT03333343 2026-01-16

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Novartis

Phase 1 Active not recruiting
105 enrolled
Thoracic

EGFR-mutant Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡